|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.430 USD | -6.93% |
|
+14.47% | -38.56% |
| 06-30 | Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell 3000E Value Index | CI |
| 06-30 | Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell 3000 Value Index | CI |
Sales 2024 by Business Segment
Sales 2024 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Research and Development of Immunotherapies and Vaccines | 8.19M | 4.41M | -68K | 426K | 20K | |||||
Total Assets | 245M | 219M | 207M | 211M | 139M | |||||
Interest Expense | -9.42K | -5.66K | -8K | -35K | -9K | |||||
Income Tax Expense | -5.42M | - | -197K | - | - | |||||
CAPEX | -342K | -12.31M | -126K | -47K | - | |||||
EBT | -54.46M | -97.09M | -84.91M | -88.45M | -95.06M | |||||
D&A | 298K | 551K | -205K | 477K | 238K | |||||
Operating Income | -54.8M | -96.91M | -87.74M | -95.93M | -103M | |||||
Net Income | -49.04M | -97.09M | -84.71M | -88.45M | -95.06M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | - | - | - | - | - | |||||
Interest Expense | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
Net Income | - | - | - | - | - | |||||
EBT | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - |
- Stock Market
- Equities
- ALT Stock
- Financials Altimmune, Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition